Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 17:5:41-48.
doi: 10.1016/j.jdin.2021.06.006. eCollection 2021 Dec.

Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel

Alison Layton  1   2 , Andrew Alexis  3 , Hilary Baldwin  4   5 , Stefan Beissert  6 , Vincenzo Bettoli  7 , James Del Rosso  8   9 , Brigitte Dréno  10 , Linda Stein Gold  11 , Julie Harper  12 , Charles Lynde  13   14 , Diane Thiboutot  15 , Jonathan Weiss  16 , Jerry Tan  17   18
Affiliations

Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel

Alison Layton et al. JAAD Int. .

Abstract

Background: The physical sequelae of acne include erythema, hyperpigmentation, and scarring, which are highly burdensome for patients. Early, effective treatment can potentially limit and prevent sequelae development, but there is a need for guidance for and evidence of prevention-oriented management to improve patient outcomes.

Objective: To identify unmet needs of acne sequelae and generate expert recommendations to address gaps in clinical guidance.

Methods: The Personalizing Acne: Consensus of Experts panel of 13 dermatologists used a modified Delphi approach to achieve a consensus on the clinical aspects of acne sequelae. A consensus was defined as ≥75% of the dermatologists voting "agree" or "strongly agree." All voting was electronic and blinded.

Results: The panel identified gaps in current guidance and made recommendations related to acne sequelae. These included identification and classification of sequelae, pertinent points to consider for patient consultations, and management aimed at reducing the development of sequelae.

Limitations: The recommendations are based on expert opinion and made in the absence of high-quality evidence.

Conclusions: The identified gaps should help inform future research and guideline development for acne sequelae. The consensus-based recommendations should also support the process of consultations throughout the patient journey, helping to reduce the development and burden of acne sequelae through improved risk factor recognition, early discussion, and appropriate management.

Keywords: Delphi process; PACE, Personalising Acne: Consensus of Experts; acne scarring; acne sequelae; acne-induced hyperpigmentation; acne-induced macular erythema; consensus; postinflammatory erythema; postinflammatory hyperpigmentation.

PubMed Disclaimer

Conflict of interest statement

All panel members received honoraria from Galderma for participating in this project. Dr Layton has acted as an advisor or consultant, been a chief investigator for research (funded to institution), and/or received honoraria for unrestricted educational events from 10.13039/501100009754Galderma, La Roche-Posay, L'Oreal, LEO Pharma, Cipher, Proctor and Gamble, Almirall, GSK, and Origimm. Dr Alexis has received grant/research support from LEO Pharma, Novartis, Almirall, Bristol-Myers Squibb, Amgen, Menlo, 10.13039/501100009754Galderma, Valeant (Bausch Health), Cara and Arcutis; has acted as a consultant for LEO Pharma, Novartis, Menlo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L'Oreal, Bristol-Myers-Squibb, Menlo, Scientis, Bausch health, UCB, Foamix, Cassiopea, Arcutis, Janssen, Allergan, Almirall, AbbVie and Sol-Gel; and has acted as a speaker (unbranded) for Regeneron, SANOFI-Genzyme, Pfizer, and AstraZeneca. Dr Baldwin has acted as an investigator, consultant, and/or speaker for Almirall, Bausch, Cassiopea, EPI Health, Galderma, La Roche-Posay, L'Oreal, Mayne Pharma, Sol-Gel, Sun Pharma, and Vyne. Dr Beissert has acted as an advisory board member for AbbVie Deutschland GmbH and Co KG, Actelion Pharmaceuticals Deutschland GmbH, Amgen GmbH, Celgene GmbH, Galderma Laboratorium GmbH, Janssen-Cilag GmbH, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, MSD Sharp and Dohme GmbH, Menlo Therapeutics, Sanofi-Aventis Deutschland GmbH, Pfizer Pharma GmbH, and UCB Pharma GmbH and has received speaker honorarium from Novartis Pharma GmbH, AbbVie Deutschland GmbH and Co KG, MSD Sharp and Dohme GmbH, Pfizer Pharma GmbH, Janssen-Cilag GmbH, Galderma Laboratorium GmbH, Celgene GmbH, La Roche-Posay Laboratoire Pharmaceutique, Actelion Pharmaceuticals Deutschland GmbH, GlaxoSmithKline GmbH and Co KG, Bristol-Myers Squibb GmbH and Co KGaA, Sanofi-Aventis Deutschland GmbH, Almirall-Hermal GmbH, and Sandoz/HEXAL AG. Dr Bettoli has acted as a consultant, advisory board member, and research investigator; received honoraria from AbbVie, Baiersdorf, Bioderma, Biogena, Difa-Cooper, Galderma, GSK, ICF, LEO Pharma, L'Oreal, Meda, Menarini – Relife, Mylan, Novartis, Pharcos-Biodue, UCB Pharma; and received research support (funds to institution) from AbbVie. Dr Rosso has acted as a research investigator, consultant, and/or speaker for Almirall, Bausch Health (Ortho Dermatology), BiopharmX, EPI Health, Galderma, LEO Pharma, Mayne Pharma, Sol-Gel, Sonoma, Sun Pharma, and Vyne Therapeutics (Foamix). Dr Dréno has acted as a consultant for Galderma. Dr Gold has acted as an investigator or advisor and/or speaker for Galderma, Ortho Derm, Sun Pharma, Sol-Gel, Foamix, Novartis, and Almirall. Dr Harper has acted as a consultant for Almirall, BioPharmX, Cassiopea, Cutera, EPI, Foamix, Galderma, Ortho, Sol-Gel, and Sun Pharma. Dr Lynde has acted as a principal investigator, speaker, and consultant for Cipher Pharma, Bausch Health, Galderma, Johnson and Johnson, GSK, and Valeant. Dr Thiboutot has acted as a consultant for Cassiopea, Galderma, and Novartis. Dr Weiss has acted as an investigator or advisor and/or speaker for Galderma, Ortho Derm, Foamix, Novartis, Almirall, Dr. Reddy's, and EPI Health. Dr Tan has acted as an advisor, consultant, investigator, and/or speaker and received grants/honoraria from Bausch, 10.13039/501100009754Galderma, Pfizer, Almirall, Boots/Walgreens, Botanix, Cipher Pharmaceuticals, 10.13039/501100009754Galderma, Novan, 10.13039/100004336Novartis, Promius, Sun Pharma, and Vichy.

Figures

Fig 1
Fig 1
The Personalising Acne: Consensus of Experts modified Delphi process.
See this image and copyright information in PMC

References

    1. Layton A.M., Thiboutot D., Tan J. Reviewing the global burden of acne: how could we improve care to reduce the burden? Br J Dermatol. 2021;184(2):219–225. doi: 10.1111/bjd.19477. - DOI - PubMed
    1. Kang S., Lozada V.T., Bettoli V., et al. New atrophic acne scar classification: reliability of assessments based on size, shape, and number. J Drugs Dermatol. 2016;15(6):693–702. - PubMed
    1. Boen M., Jacob C. A review and update of treatment options using the acne scar classification system. Dermatol Surg. 2019;45(3):411–422. - PubMed
    1. França K., Keri J. Psychosocial impact of acne and postinflammatory hyperpigmentation. An Bras Dermatol. 2017;92(4):505–509. - PMC - PubMed
    1. Bae-Harboe Y.S., Graber E.M. Easy as PIE (postinflammatory erythema) J Clin Aesthet Dermatol. 2013;6(9):46–47. - PMC - PubMed

LinkOut - more resources